Introduction
The cardiac autonomic nervous system represents an important therapeutic target for modulation of atrial and ventricular arrhythmias. Current therapies involving blockade of the sympathetic nervous system including beta-blockers, angiotensin-converting enzyme inhibitors, and aldosterone antagonists have been the cornerstones for the treatment of arrhythmias and heart failure. However, there is growing attention and need for therapies targeting the parasympathetic nervous system to compliment and augment our current approach.
Parasympathetic imbalance, as manifested by abnormal heart rate variability and decreased baroreceptor sensitivity, is a well-established manifestation of heart failure and increases the risk of sudden cardiac death [1] [2] [3] [4] [5] [6] . Furthermore, an increase in parasympathetic tone portends a greater likelihood of survival in the setting of ischemia [7] . Vagal nerve stimulation (VNS) represents a potential approach to increase parasympathetic efferent outflow and compensate for the parasympathetic dysfunction that increases the risk of arrhythmias [8] .
Anatomy and physiology of vagal nerve stimulation
The vagosympathetic trunk synapses in the nucleus tractus solitarius and contains efferent fibers originating in the nucleus ambiguus and dorsal motor nucleus of the brainstem [9] and, therefore, contains both efferent and afferent neural fibers (Fig. 1) . Visceral efferent fibers synapse near target organs, whereas afferent fibers traveling through the vagus via the bipolar neurons of the nodose ganglia (inferior vagal ganglion) carry information to the brainstem and higher centers. Within the vagosympathetic trunk, there is a predominance of parasympathetic neural fibers, although sympathetic nerve fibers also exist [10, 11] . The cardiomotor preganglionic parasympathetic nerve fibers converge and synapse within the intrinsic cardiac nervous system ganglia, lying on the dorsal and ventral fat pads on the basal aspect of the heart. The intrinsic cardiac nervous system forms a complex neural network that responds to and maintains fine control of cardiac function [12, 13] . The postganglionic parasympathetic fibers from the ganglia within these fat pads then innervate the sinoatrial and atrioventricular nodes as well as the atrial and the ventricular myocardia [14] .
It is important to note that VNS can have different effects depending on the parameters and level of stimulation used. High-level stimulation, particularly at frequencies 920 Hz, significantly reduces heart rate (960 %) and increases AV nodal conduction time [15] . At these high stimulation thresholds, VNS can induce asystole and complete heart block [16] . With medium-level stimulation, mild reductions in heart rate (10-50 %) and prolongation in AV nodal conduction time are observed. Low-level vagal nerve stimulation is defined as combination of intensity and frequency which has no effect on heart rate or AV conduction. With high-or medium-level VNS, atrial effective refractory period is shortened while with low-intensity stimulation, the atrial effective refractory period prolongs [17] . There is a threshold effect for voltage and pulse duration [18] . Increasing frequencies up to 17 Hz causes progressive sinus bradycardia while stimulation at 20-40 Hz (with voltage and pulse width held constant) can lead to prolonged pauses with junctional or ventricular escape beats. Therefore, there is an optimal range of frequencies and output to achieve the desired rhythm and degree of bradycardia [18] .
Neural modulation of ventricular arrhythmias with VNS
VNS has multiple electrophysiological effects on the ventricular myocardium. VNS lengthens the ventricular effective refractory period [19] [20] [21] [22] [23] and attenuates the shortening effects of stellate stimulation on refractory period as measured using VF intervals [24] . Right and left VNS have similar efferent electrophysiological effects on ventricular activation recovery intervals (ARI), a surrogate of action potential duration. Stimulation of both vagi increases ARI on all regions of the epicardium, though greater prolongation on the endocardium compared to the epicardium is observed [20] . The effects of VNS on ventricular arrhythmias have been studied in the setting of myocardial ischemia, both in normal and previously infarcted hearts. In various animal models of rats, cats, rabbits, and canines, VNS has been shown to reduce the incidence of ventricular fibrillation (VF) and increase VF threshold [19, 25-35, 36•, 37•, 38] whereas vagotomy decreased VFT [39] . In a canine model of coronary artery ligation, high-intensity VNS decreased the time to spontaneous VF in the setting of ischemia compared to controls without VNS [25] . In rats 3 months after myocardial infarction, premature ventricular contractions (PVCs) were significantly decreased with low-medium-intensity VNS when the heart rate was suppressed by 20-30 beats per minute (~10 %) [40] . Interestingly, the effects were noted 1-2 days after initiation of intermittent VNS and lingered for several days after cessation of VNS therapy, suggesting a remodeling process or memory that modulates the effects on ventricular ectopy over time [40] . VNS at an intensity to lower heart rate in a canine ischemia model to 60-100 bpm was shown to improve survival and reduce the time to spontaneous VF [27] . In rabbits in whom ventricular arrhythmias are induced by sympathetic activation via stimulation of the ansae subclaviae or by QT prolongation using intravenous cesium chloride, Fig. 1 . The afferent bipolar neurons that lie in the inferior vagal ganglia (nodose ganglia) are bipolar neurons that transmit signals from the myocardium to the brainstem via the vagosympathetic trunk and synapse in the nucleus tractus solitarius. The cardiomotor efferent fibers in the vagosympathetic trunk originate in the brainstem from the nucleus ambiguus and dorsal motor nucleus and are preganglionic fibers that synapse on the neurons of the intrinsic cardiac nervous system. These neurons subsequently provide postganglionic parasympathetic innervation to the right and left ventricular myocardia, right and left atria, and sinus and atrioventricular nodes.
medium-intensity VNS preferentially reduced polymorphic ventricular tachycardia (VT) rather than monomorphic VT [30, 41] . VNS has also been shown to reduce the restitution slope to G1 [19, 35] , thereby protecting against malignant arrhythmias [42] .
Bradycardia is one mechanism behind the protection conferred by VNS. In the setting of acute cardiac ischemia, reducing heart rate can improve the supply-demand mismatch and thereby reduce electrical vulnerability to malignant arrhythmias. Pacing the atria [32] and ventricles [31, 43] at fixed rates, while performing VNS attenuates its protective effects in this setting. The traditional interpretation of this pacing effect was that the heart rate reduction itself is protective; however, there are new studies to suggest that pacing itself can be pro-arrhythmic by increasing sympathetic tone [44, 45] and by altering the neural activation patterns in the intrinsic cardiac ganglia [46] .
Another mechanism behind the anti-arrhythmic effects of VNS may involve preservation of electrotonic coupling and thereby electrical stabilization of the myocardium. Reduction of electrotonic coupling has been linked to arrhythmogenesis in ischemia [47] . VNS preserves electrotonic coupling during ischemia along with reducing ST segment elevations and dispersion of repolarization [47] . Interestingly, in the same study, pacing attenuated the protective effects of VNS whereas bilateral stellectomy did not, further supporting the notion that VNS mediates its effects by direct innervation of the heart rather than by causing reflex activation of afferent fibers in the central nervous system. A summary of the mechanisms behind the beneficial effects of VNS is shown in Table 1 .
The utility of VNS in the setting of chronic myocardial infarction is currently unknown. There is limited literature examining the effects of low-to-mediumintensity VNS on the mature post-infarct scar. In one study, high-intensity VNS caused VT in setting of significant bradycardia that degenerated into VF [22] . Preliminary data suggest, however, that low-to medium-level VNS may reduce ventricular arrhythmias. In a chronic porcine infarct model, VNS at moderate levels (10 Hz, 1 ms) decreased global dispersion of repolarization and VT inducibility [48] .
At the synaptic level, multiple messengers transduce the effects of VNS. Muscarinic receptors activated by acetylcholine have a clear role in reducing ventricular arrhythmias, which is reversed with atropine [49] . There are five types of cardiac muscarinic receptors [50] , and the M3 receptor subtype along with the nicotinic receptor alpha-7nAChR play a dominant role in mediating the cardiac protective effects of acetylcholine [51] . Nitric oxide has also been shown to mediate some of the effects of VNS on the VF threshold and action potential restitution slope, but not on effective refractory period prolongation [19] . Nitric oxide is increased with VNS and works independently of muscarinic receptor activation [36•] .
Gap junction downregulation has been implicated in the genesis of arrhythmias with connexin-43 activity levels (regulated by phosphorylation) being closely linked to the pathogenesis of arrhythmias [52] . In an ischemia-induced VF rat model, connexin-43 phosphorylation is reduced with ischemia and preserved with VNS [34] . Inhibition of connexin-43 with carbenoxolone negates both connexin-43 phosphorylation and the protection from VF by VNS [37•] . Furthermore, aging is associated with reduced connexin-43 expression and aged rats demonstrate a decrease in the protective effects of VNS on ischemia-induced VF [37•] .
Finally, VNS can cause remodeling of the stellate ganglia neurons. In dogs subjected to low-level left vagal stimulation for 1 week, left stellate ganglion neurons demonstrated increased expression of a small conductance calciumactivated potassium channel, SK2. SK channels are responsible for the slow afterhyperpolarization, hyperpolarizing neurons and decreasing neuronal firing. This data suggests that VNS can lead to beneficial remodeling of the sympathetic nervous system [53] .
Not all neurotransmitters released with VNS, however, are protective. When cholinergic effects on heart rate (HR) suppression are eliminated with atropine, VNS causes a surprising increase in HR, primarily through the release of vasoactive intestinal peptide (VIP) [36•, 47, 54] . Additionally, VIP does not seem to protect against ventricular arrhythmias and does not affect VF threshold or ventricular effective refractory period [36•] . Given that the vagal trunk contains a variety of nerve fibers and VNS releases a number of neurotransmitters, characterization of the neurotransmitters and their effects is important prior to its utilization for therapeutic purposes.
The anti-arrhythmic benefits of VNS appear to be dependent on stimulation parameters as well as whether continuous (which often leads to more bradycardia) or intermittent stimulation is utilized (Table 2) . Although VNS reduces ischemia-induced VF and VT, stimulation of the vagosympathetic trunk at high frequencies (920 Hz) and at intensities that cause severe bradycardia or asystole can induce bigeminy [55] [56] [57] [58] and monomorphic VT [15, 30, 55] . With highintensity VNS in the setting of acute and chronic ischemia, monomorphic VT can be induced, which can degenerate into VF [22] . The genesis of the PVCs induced by high-intensity VNS has been attributed to sinus arrest and/or AV nodal blockade which unmasks the underlying ventricular automaticity [18] . This phenomenon is eliminated when ventricle is paced faster than underlying ventricular escape rate [59] . The unmasking phenomenon of PVCs also carries over to VT [30, 55, 57] . Scherf et al. in 1962 [55] showed that occurrence of ventricular couplets with VNS was more frequent when the sinus rhythm rate was lowered from 175 beats per minute (bpm) to less than 100 bpm in a canine model. Therefore, the pro-arrhythmic effects of VNS appear to occur when highlevel stimulation unmasks the underlying ventricular automaticity due to suppression of supraventricular pacemakers, and there also exists either the simultaneous presence of the substrate for reentry, such as ischemia [59] , concurrent sympathetic nerve stimulation [30] , or local sodium chloride injections [55] . Manning and colleagues, in normal cat hearts, induced a series of ventricular ectopic beats or idioventricular rhythm with medium stimulation intensity of 10 Hz (3-8 V, 2 ms) [57] , in the setting of simultaneous right stellate ganglion stimulation. Therefore, the majority of arrhythmias observed in this setting are idioventricular rhythms, rather than ventricular tachycardia. An additional hypothesis for the etiology of the observed ventricular automaticity is the possibility that high-intensity VNS can activate afferent fibers, causing a reflex sympathetic response, or may be stimulating the intrinsic sympathetic fibers within the vagal trunk. Indeed, in a rabbit ischemia model where intermittent VNS leads to a reduction in infarct size, continuous VNS for 10 min increased infarct size, while bilateral vagotomy or beta-blockers abolished this deleterious effect. Of note, the continuous stimulation also leads to significant bradycardia and an increase in loading conditions and wall stretch of the atria, which likely activated the reflex sympathetic nervous system [60•] . Thus, the majority of studies show protection against malignant ventricular arrhythmias at low-to moderate-level intermittent VNS, with the goal of modest to minimal lowering of heart rate at lower frequencies to prevent afferent fiber stimulation.
Certain populations of patients with predispositions to ventricular arrhythmias are unlikely to benefit from VNS. Early repolarization syndrome [61], Brugada [62], LQT3 [63] , and some subgroups of idiopathic VT [64] are known to have parasympathetic triggers, and VNS in these settings is likely to be proarrhythmic. Furthermore, a case report of VNS implantation to treat electrical storm exacerbating ventricular arrhythmias in an ischemic cardiomyopathy patient has been reported [65] . These studies demonstrate the importance of identifying the correct patient population and appropriate stimulation thresholds and frequencies prior to consideration of VNS for prevention of VT/VF.
Modification of atrial arrhythmias
Acetylcholine challenge has been known to facilitate triggering of atrial fibrillation (AF) [67] , and the combination of parasympathetic and sympathetic activation is thought to play an important role in the genesis of AF. In particular, with medium-to high-level stimulation, VNS can induce AF [66, 68, 69] . In a canine pacing-induced AF model, VNS became pro-arrhythmic at intensities that decreased heart rate more than 40 % [70] . High-intensity VNS reduces atrial effective refractory period (AERP) [68, 71] , may preferentially affect right AERP more than left [72] , increases AERP dispersion [68, 73, 74] , causes a heterogeneity in atrial conduction leading to wave front breaks [75, 76] , reduces AF threshold, and prolongs duration of AF [77] . The pro-arrhythmic effects of VNS that lead to AF have been shown to be mediated by acetylcholine activation of nicotinic receptors [71] and VIP [77] . More recently, low-level VNS has been shown to have anti-arrhythmic properties, particularly with regard to AF. Typical stimulation frequencies used for low intensity were G20 Hz with energies of 1-5 V and the goal of avoiding bradycardia. AF or atrial tachycardia in the setting of rapid burst atrial pacing of ambulatory dogs was reduced with low-level VNS [78] . In Table 2 normal canine hearts, AF duration induced by direct topical application of acetylcholine to the right atrial appendage or extra-stimulus atrial pacing was reduced with low-level VNS [79] . In the setting of electrical stimulation of anterior right and superior left ganglionated plexi, low-level VNS reduced AF inducibility with extra-stimulus atrial pacing [80] . Low-level VNS increased AF threshold in response to high-frequency stimulation near the pulmonary veins and atrial appendages during the atrial refractory period and blunted the chronotropic response to right stellate ganglion and superior left ganglionated plexi stimulation [81, 82] . Finally, low-level right VNS decreased AF duration in a rabbit model of obstructive sleep apnea [83•] . With regard to its mechanisms, low-level VNS has opposite effects on atrial myocardium compared to high-and medium-level stimulation. In addition to increasing AF threshold, it has been shown to increase AERP and reduce AERP dispersion [80] and AF duration [79] . Low-level VNS reduces left stellate ganglion nerve activity and, in fact, has been shown to cause beneficial remodeling in the stellate ganglia with an increase in nontyrosine hydroxylase-and choline acetyltransferase-positive neurons [78] . As mentioned above, an additional potential mechanism for the antiarrhythmic properties attributed to low-level VNS is the upregulation of small conductance calcium-activated potassium channel type 2 among stellate ganglion neurons, which reduces the overall activity of these neurons [53] . Although topical application of acetylcholine to atrial tissue induces AF, downstream cell signaling mediators of acetylcholine such as nitric oxide and PI3K have anti-arrhythmic properties [17] . Vasostatin-1 may also be one of the mediators of the beneficial effects of low-level VNS. Injection of vasostatin-1 into the autonomic ganglia demonstrates similar anti-arrhythmic effects as low-level VNS, reducing AF inducibility and leading to the release of nitric oxide and PI3K [79] , although immunohistochemical data regarding the presence of vasostatin-1 in cardiac autonomic ganglia is lacking. The mechanisms behind the protective effects of VNS on atrial arrhythmias are summarized in Table 1 .
It should be noted, however, that certain subgroups of patients with vagally mediated AF may not benefit from low-level VNS. Vagally mediated AF is a welldescribed entity in which patients experience paroxysmal AF that primarily occurs at night, at rest, or with digestion or swallowing. These patients do not respond to treatments with digoxin, beta-blockers, or verapamil and have been successfully treated with fixed atrial pacing [84] . There is no data that VNS would be of any benefit in these patients. Improvement in heart failure as an additional mechanism for the beneficial effects of VNS on arrhythmias
The hemodynamic response to VNS tends to be one of decreased inotropy and chronotropy without a significant change in diastolic function. A decrease in LV systolic pressure [85, 86] and load-independent parameter of end-systolic elastance [87, 88] is observed. Much of the negative inotropic effects can be overcome by holding the heart rate constant with pacing [85, [89] [90] [91] . However, there also exist interspecies variations. In rats, an unexpected increase in inotropic response to medium-intensity bilateral VNS (10 Hz, 10 V, 3 ms) is observed, which may be due to the paucity vagal innervation in the rat ventricle [89] . Furthermore, positive inotropic effects of VNS on the right ventricle (RV) have been demonstrated in the setting of muscarinic and sympathetic blockade. VIP has been implicated as the molecular mediator of this effect [92] .
In a variety of animal models of heart failure, VNS improves cardiac function and even survival. In a canine heart failure model, VNS combined with betablockers was superior to beta-blockers alone in improving left ventricular ejection fraction (LVEF) [93] . In a canine pacing-induced heart failure model, chronic intermittent VNS with the goal of decreasing heart rate by 20 bpm improved left ventricular (LV) end-diastolic and end-systolic volumes, LVEF, heart rate variability, and baroreflex sensitivity [94] . Similar improvements in LVEF and LV end-systolic volume were shown in an infarct heart failure canine model with low-level VNS [95] . VNS attenuates much of the detrimental effects of ischemia. Low-medium VNS reduces infarct size [96] [97] [98] , lowers LVEDP, raises dp/dt, reduces biventricular weight, decreases LV dilation and wall thinning, and improves survival rate [99] . Intermittent VNS compared to continuous VNS [98] and initiating VNS during ischemia as opposed to after ischemia [97] seems to increase these beneficial effects. It is important to understand, however, that variability in stimulation parameters and interspecies differences may lead to unexpected outcomes, particularly during continuous stimulation with significant bradycardia, which can lead to reflex sympathetic activation or activating sympathetic efferents via activation of vagal afferent fibers [60•] .
The mechanisms of the effects of VNS on cardiac function are still under investigation. Calcium influx is reduced when VNS is performed in the setting of sympathetic stimulation, but not when VNS is performed alone [85] . Modulation of sympathetic function via presynaptic inhibition of norepinephrine release has also been shown [100] . The anti-inflammatory effects, described below, also play an important role in reducing infarct size and improving cardiac function. Finally, VNS causes vasodilation, an effect mediated by acetylcholine and nitric oxide, as well as VIP [101] [102] [103] . VNS increases coronary blood flow in situ in normal canine hearts, an effect that is reduced by infusion of a VIP receptor antagonist [(4Cl-D-Phe 6 , Leu 17 )VIP]. VIP is released at 10-20-Hz stimulation frequencies in the coronary vasculature and throughout the myocardium [102] and is a potent vasodilator (greater than adenosine or nitroprusside) [104] . It interacts with VIP receptors (VPAC1 and VPAC2), activates the adenylyl cyclase signaling cascade, leading to vasodilation and increase in inotropy and chronotropy. The vasodilatory effects could mediate the reduction in infarct size observed when applied simultaneously with ischemia due to coronary occlusion in a porcine model [97, 98] . Of note, in normal canine hearts, VIP released by VNS in the setting of muscarinic and beta receptor blockade augments right ventricular contraction, relaxation, and heart rate [92] .
Heart failure is known to affect the levels of the three isoforms of nitric oxide synthase: endothelin nitric oxide (eNOS), inducible nitric oxide (iNOS), and neuronal nitric oxide (nNOS). eNOS is significantly decreased in heart failure [93, 105, 106] . iNOS has an important role in generating oxidative radicals, bradyarrhythmias, and fibrosis and is increased in heart failure [93, 107] . nNOS has also been shown to be elevated in heart failure [93, 108] . The effects of VNS on the various isoforms of nitric oxide were demonstrated by Hamann and colleagues who showed that 6 months of low-level VNS in a chronic infarct heart failure model leads to an increase in eNOS, decrease in nNOS, and normalization of nNOS levels [95] .
Currently, there are three large human clinical trials assessing the effect of VNS as a treatment option for heart failure. A pilot study in 2008 showed improvement in New York Heart Association (NYHA) class heart failure (HF), Minnesota quality of life, and LV end-systolic volume [109] . ANTHEM-HF, a nonblinded study which includes adults with NYHA functional class II-III, LVEF G40 %, LV end-diastolic diameter between 50 and 80 mm, QRS G150 ms, on optimal medical therapy for 3 months, showed improvements in LVEF (4.5 %), LV end-systolic volume (−4.1 mL), LV end-systolic dimension (−1.7 mm), HR variability, 6 min walk test, and NYHA class in 77 % of patients. No notable difference between right and left sided vagal stimulation has been observed in this trial, similar to that seen in translational studies [110] . NECTAR-HF is an ongoing randomized blinded study that enrolled adults with LVEF G=35 %, NYHA class II-III, and on optimal medical therapy for at least 1 month. The 6-month results showed an improvement in heart failure score and an increase in heart rate variability. However, there was no significant difference in LVEF, LV dimensions, or peak VO 2 (oxygen consumption rate) [111] . INOVATE-HF is another ongoing clinical trial to assess long-term outcomes of VNS in patients with LVEF G40 %, NYHA class III QRS G120 ms, and LV end-diastolic dimension of 50-80 mm [112] .
Anti-inflammatory effects of VNS
Low-to medium-intensity VNS has significant anti-inflammatory effects that may also explain much of its benefit. In a canine pacing-induced heart failure model, the rise in plasma norepinephrine, angiotensin II, and CRP levels were attenuated with medium-intensity VNS [94] . In a post-infarct porcine model, low-medium-intensity VNS reduced production of mitochondrial reactive oxygen species and release of cytochrome-c [97, 98] . While continuous VNS increased inflammatory markers in a rabbit model of ischemia, potentially by activating the reflex sympathetic nervous system, intermittent VNS and decentralization of vagus eliminated these deleterious effects [60•] . Similar beneficial effects of intermittent VNS compared to continuous VNS have been observed in an ischemic porcine model where low-level left VNS attenuated ventricular dysfunction through prevention of mitochondrial dysfunction [98] . Oxidative stress is also modified by VNS. In a mouse chronic heart failure model 28 days post-infarct, medium-intensity VNS reduced the production of radical oxygen species [113, 114] .
The effects of VNS on TNF-alpha are controversial and may be species dependent. TNF-alpha has historically been considered a harmful inflammatory mediator. Its levels are variably affected by VNS depending on the species. Studies in rats [51, 115] and rabbits [96] with medium-level VNS have shown TNF-alpha levels increase with ischemia, an effect that is attenuated with VNS. TNF-alpha is also reduced by low VNS in a canine microembolization heart failure model [95] , in endotoxin-exposed rats [116] , and in heatstroke-exposed rats [117] . These anti-inflammatory effects are in alignment with the known anti-inflammatory effects of acetylcholine, which inhibits the synthesis of TNF-alpha in the liver and spleen as well as the heart [118] . On the other hand, TNF-alpha has pleiotropic effects and can function as a protective inflammatory molecule mediating ischemic preconditioning and prevention of heart failure in mice [119] . In contrast to other studies, an increase in TNF-alpha level was observed in a mice model of acute ischemia, though VNS in this study was still protective [119] . These differences may be explained by the effects of VNS on TNF receptors, rather than TNF levels. VNS in this study simultaneously increased protective TNFR2 and downregulated the destructive TNFR1, which imparted an overall protective effect to TNF-alpha, and attenuated infarct size [119] .
VNS also affects levels of interleukins (IL). Pro-inflammatory IL-6 is reduced with low-level VNS in canine heart failure model [95] , medium-level VNS in rat ischemia model [115] , medium-level VNS in dog ischemia model [120] , and in a rat heatstroke model [117] . Pro-inflammatory IL-1 and lipopolysaccharideinducible CXC chemokine (LIX, IL-8 analogue in rats) were attenuated in the presence of medium-intensity VNS in ischemic rat models [51, 115, 121] . Antiinflammatory IL-4 is increased in a post-infarct porcine model with low-to medium-intensity VNS [97] .
Other inflammatory markers are generally reduced across various studies. A decrease in neutrophil count, MMP-8, and MMP-9 is observed with medium-level VNS in rabbits undergoing coronary occlusion [96] . Monocyte chemoattractant protein (MCP)-1 is increased with ischemia, and the increase is attenuated in the presence of medium-intensity VNS in an ischemic rat model [121] . Thus, the current studies support an antiinflammatory role for low-to medium-intensity intermittent VNS.
Conclusions
VNS has shown promise in reducing malignant ventricular arrhythmias, particularly in the setting of ischemia, as well as atrial arrhythmias, particularly AF. The improvement in heart failure and the antiinflammatory and vasodilatory properties of VNS provide additional antiarrhythmic benefit. Given the complexity of the cardiac autonomic nervous system, including the presence of both afferent and efferent as well as parasympathetic and sympathetic fibers in the vagosympathetic trunk, it is critical to carefully elucidate the mechanisms of VNS and the parameters of stimulation to ensure that vagal nerve stimulators achieve the desired therapeutic effect.
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